BMS appoints Christopher Perley as Devens general manager
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibbhas named Christopher Perley vice-president and general manager of its Devens, Massachusetts biologics manufacturing facility. He will be responsible for continuing the supervision of the project to build the facility and will have overall management responsibility for the site when it becomes operational in 2011. Mr Perley was previously vice-president of network strategy at Wyeth Biotech. He has also held manufacturing and biotechnology process development roles at the Genetics Institute and Roche.
You may also be interested in...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.